Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sucrosofate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 6/20 | 0.72 |
| ▸ | FGF2 | P09038 | 4/20 | 0.72 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 13/20 | 0.35 |
| ▸ | VEGFA | P15692 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrosofate SCHEMBL145069 | 0.99 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL145070 | 0.99 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL16661862 | 0.99 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL18467935 | 0.99 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL16661861 | 0.99 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL18742107 | 0.98 | FGF1 (0.72) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL18244210 | 0.92 | FGF1 (0.65) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL19358882 | 0.92 | FGF1 (0.65) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL2063889 | 0.92 | FGF1 (0.65) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Water SCHEMBL41379 | 0.89 | FGF1 (0.61) | FGF1FGF2SERPINC1HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117750944-A | Vinorelbine tartrate liposome and raw material composition, preparation method and application thereof | 上海济煜医药科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| WO-2023051799-A1 | VINORELBINE TARTRATE LIPOSOME, AND RAW MATERIAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海济煜医药科技有限公司 | 2023-04-06 | — | — | WO | claimed |
| CN-103181897-B | Gefitinib liposome preparation and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL | 2015-06-10 | — | — | CN | claimed |
| CN-102485212-B | Sunitinib malate liposome and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL | 2014-04-09 | — | — | CN | claimed |
| CN-103181897-A | Gefitinib liposome preparation and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL | 2013-07-03 | — | — | CN | claimed |
| CN-102805729-A | Vinflunine liposome preparation and preparation method of vinflunine liposome preparation | QILU PHARMACEUTICAL CO LTD | 2012-12-05 | — | — | CN | claimed |
| CN-102485212-A | Sunitinib malate liposome and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL | 2012-06-06 | — | — | CN | claimed |
| US-4990610-A | Reacting Sucrose with Chlorosulfonic acid and 2-Picoline | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1991-02-05 | — | — | US | claimed |
| WO-1990002133-A1 | METHOD FOR PREPARING SUCRALFATE AND AAI-10001 | FORMULATIONS DEVELOPMENT LABORATORIES, INC. (US) | 1990-03-08 | — | — | WO | claimed |
| CN-117750944-A | Vinorelbine tartrate liposome and raw material composition, preparation method and application thereof | 上海济煜医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023190709-A1 | LIPOSOME COMPOSITION AND LIPOSOME-CONTAINING PHARMACEUTICAL COMPOSITION | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-11771651-B2 | Liposomes and uses thereof | ACADEMIA SINICA (TW) | 2023-10-03 | — | — | US | disclosed |
| WO-2023072890-A1 | PROCESS FOR THE PREPARATION OF SUCROSE OCTASULFATE OCTAKISTRIETHYLAMMONIUM SALT (TASOS) POWDER AND USES THEREOF | SANDOZ AG (CH) | 2023-05-04 | — | — | WO | disclosed |
| EP-4169928-A1 | PROCESS FOR THE PREPARATION OF SUCROSE OCTASULFATE OCTAKISTRIETHYLAMMONIUM SALT (TASOS) POWDER AND USES THEREOF | SANDOZ AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| EP-0691976-A1 | ANTICOAGULANT COMPOUNDS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022885-A1 | ANTICOAGULANT COMPOUNDS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022437-A2 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1994-10-13 | — | — | WO | disclosed |
| US-5084446-A | Reaction of aluminum chlorohydrate and sucrose octaammonium sulfate | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1992-01-28 | — | — | US | disclosed |
| US-4990610-A | Reacting Sucrose with Chlorosulfonic acid and 2-Picoline | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1991-02-05 | — | — | US | disclosed |
| WO-1990002133-A1 | METHOD FOR PREPARING SUCRALFATE AND AAI-10001 | FORMULATIONS DEVELOPMENT LABORATORIES, INC. (US) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771651-B2 | Liposomes and uses thereof | LYPLAL1, SMPD1, LGMN | FGF1 4326/4885FGF2 4197/4885SERPINC1 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.